Evidence map›Paper›PMID 31441367›Full record

ArticlemAbs

Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification.

Weixin Jin, Zizhuo Xing, Yuanli Song, Chao Huang, Xuankuo Xu, Sanchayita Ghose, Zheng Jian Li

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Study of Oncolytic Virus Preservation and Formulation.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  10. Disassembly of Amyloid Fibril with Infrared Free Electron Laser.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 3 countries.

Weixin JinBiologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb , Devens , MA , USA.ORCID 0000-0002-5875-9402
Zizhuo XingBiologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb , Devens , MA , USA.
Yuanli SongBiologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb , Devens , MA , USA.ORCID 0000-0002-5078-8049
Chao HuangBiologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb , Devens , MA , USA.ORCID 0000-0001-9355-9572
Xuankuo XuBiologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb , Devens , MA , USA.ORCID 0000-0002-5557-0284
Sanchayita GhoseBiologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb , Devens , MA , USA.
Zheng Jian LiBiologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb , Devens , MA , USA.ORCID 0000-0002-1941-4145
Bristol-Myers Squibb (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Significant amounts of soluble product aggregates were observed during low-pH viral inactivation (VI) scale-up for an IgG4 monoclonal antibody (mAb IgG4-N1), while small-scale experiments in the same condition showed negligible aggregation. Poor mixing and product exposure to low pH were identified as the root cause. To gain a mechanistic understanding of the problem, protein aggregation properties were studied by varying critical parameters including pH, hold time and protein concentration. Comprehensive biophysical characterization of product monomers and aggregates was performed using fluorescence-size-exclusion chromatography, differential scanning fluorimetry, fluorescence spectroscopy, and dynamic light scattering. Results showed IgG4-N1 partially unfolds at about pH 3.3 where the product molecules still exist largely as monomers owing to strong inter-molecular repulsions and favorable colloidal stability. In the subsequent neutralization step, however, the conformationally changed monomers are prone to aggregation due to weaker inter-molecular repulsions following the pH transition from 3.3 to 5.5. Surface charge calculations using homology modeling suggested that intra-molecular repulsions, especially between CH2 domains, may contribute to the IgG4-N1 unfolding at ≤ pH 3.3. Computational fluid dynamics (CFD) modeling was employed to simulate the conditions of pH titration to reduce the risk of aggregate formation. The low-pH zones during acid addition were characterized using CFD modeling and correlated to the condition causing severe product aggregation. The CFD tool integrated with the mAb solution properties was used to optimize the VI operating parameters for successful scale-up demonstration. Our research revealed the governing aggregation mechanism for IgG4-N1 under acidic conditions by linking its molecular properties and various process-related parameters to macroscopic aggregation phenomena. This study also provides useful insights into the cause and mitigation of low-pH-induced IgG4 aggregation in downstream VI operation.

Indexed as

Protein AggregatesProtein UnfoldingAnimalsAntibodies, MonoclonalCHO CellsCricetulusHumansHydrogen-Ion ConcentrationProtein DomainsAntibodies, MonoclonalProtein Aggregatesantibody aggregationcomputational fluid dynamicsLow pHviral inactivation

Identifiers

PMID31441367
PMCPMC6816434
OpenAlexW2969605137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.